GSK plc

LSE GSK.L

GSK plc Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -2.03 B

GSK plc Net Cash Used For Investing Activities is USD -2.03 B for the year ending December 31, 2023, a 80.86% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • GSK plc Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -10.60 B, a -340.87% change year over year.
  • GSK plc Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -2.40 B, a -181.48% change year over year.
  • GSK plc Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD 2.95 B, a 141.60% change year over year.
  • GSK plc Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -7.09 B, a -258.58% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
LSE: GSK.L

GSK plc

CEO Ms. Emma Natasha Walmsley
IPO Date July 1, 1988
Location United Kingdom
Headquarters 980 Great West Road
Employees 70,212
Sector Health Care
Industries
Description

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Similar companies

NG.L

National Grid plc

USD 11.12

-0.46%

VOD.L

Vodafone Group Public Limited Company

USD 0.82

0.78%

BP.L

BP p.l.c.

USD 5.13

-2.45%

ULVR.L

Unilever PLC

USD 54.69

-1.04%

AZN.L

AstraZeneca PLC

USD 129.77

-1.69%

StockViz Staff

January 15, 2025

Any question? Send us an email